Articles
Volume 11 Supplement 5
Severe sepsis and drotrecogin alfa (activated)
Reviews
Edited by Antonio Artigas and Claude D Martin
Publication of the supplement has been sponsored by Eli Lilly & Company
|
Review
Diagnosis and treatment of severe sepsis Yann-Erick Claessens, Jean-François Dhainaut Critical Care 2007, 11(Suppl 5):S2 (19 December 2007) |
|
Review
Recombinant human activated protein C: current insights into its mechanism of action Marcel Levi, Tom van der Poll Critical Care 2007, 11(Suppl 5):S3 (19 December 2007) |
|
Review
The protein C pathway: implications for the design of the RESPOND study Burkhard Vangerow, Andrew F Shorr, Duncan Wyncoll, Jonathan Janes, David R Nelson, Konrad Reinhart Critical Care 2007, 11(Suppl 5):S4 (19 December 2007) |
|
Review
Clinical trials in severe sepsis with drotrecogin alfa (activated) Pierre-François Laterre Critical Care 2007, 11(Suppl 5):S5 (19 December 2007) |
|
Review
The safety profile of drotrecogin alfa (activated) Roberto Fumagalli, Mariano A Mignini Critical Care 2007, 11(Suppl 5):S6 (19 December 2007) |
|
Review
Practical aspects of treatment with drotrecogin alfa (activated) Luigi Camporota, Duncan Wyncoll Critical Care 2007, 11(Suppl 5):S7 (19 December 2007) |
|
Introduction
Introduction: severe sepsis and drotrecogin alfa (activated) Antonio Artigas, Claude D Martin Critical Care 2007, 11(Suppl 5):S1 (19 December 2007) |
